Psychotherapeutic ...

Conducting psychological correction in patients in need can be combined with medication, not having side effects such as slowing of cognitive and mental activity. These drugs, in particular, non-chemical compounds and plant derivatives. In this aspect of great interest to Perseus, which consists of extracts of valerian, lemon balm, peppermint, have pronounced anxiolytic activity. Studies have shown high efficacy against Persia in anxiety disorders in psihovetetativnogo syndrome. So, was conducted placebo-controlled clinical trial of the effectiveness of this drug in 93 patients with psycho-vegetative syndrome in the structure of neurotic disorders, anxiety series [1]. The study included 62 women and 31 men. The patients' age ranged from 16 to 62 years, mean age included in the trial patients was 34.5 years. All patients were divided into 2 groups. The first group included 47 patients (30 women, 17 men, average age 34.8 years) who received Persen Forte at a dose of 1 capsule (125 mg) 2 times a day. The second group included 46 patients (32 women and 14 men, average age 35.0 years) treated with placebo, 1 capsule 2 times a day. Placebo and Persia Forte were identical in dosage form and type of packaging. The course of treatment was 28 days. Prerequisite for inclusion in the clinical trial was the lack of acceptance kakihlibo drugs within 2 weeks prior to the appointment of Persia. In this study patients underwent a neurological examination, we used the method of questionnaire survey assessing the state of the autonomic nervous system, assess the quality of sleep, the quality of life, as well as the scale of life events and Ray Holmes, a visual analogue scale for subjective evaluation of wellness, the scale of Spielberger, Beck. We analyzed the level of attention and work capacity of patients with proofreading sample test Bourdon and Schulte. The main clinical manifestations in patients enrolled in the study had increased anxiety, feelings of inner tension, irritability, phobias. A considerable number of patients had these manifestations, as tension headaches (74%), weakness (67%), fatigue (53%), feeling short of breath (80%), non-system dizziness (68%), difficulty sleeping (74 %), psychogenic cardialgia (62%). Analysis of questionnaire data showed that patients of the groups had expressed anxiety disorders, significant autonomic dysfunction and sleep disturbances, light levels of depression. All patients reported reduced quality of life against the backdrop of existing violations. Analysis of clinical manifestations in one week of treatment showed a decrease in the level of reactive anxiety, which was significantly decreased in both groups. On day 28 of therapy in both groups was noted a decrease of general weakness, fatigue, irritability, anxiety, feelings of lack of air, as well as psychogenic cardialgia.